These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 15359911

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 3. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
    Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, Avvisati G, Petrucci MT, Pulsoni A, Leone G, Sica S, Martelli M, Tabilio A, Fioritoni G, Majolino I, Mandelli F.
    Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592
    [Abstract] [Full Text] [Related]

  • 4. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S, de Wolf JT, Guikema JE, Klip H, Smit JW, Smit Sibinga CT, Bos NA, Vellenga E.
    Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
    [Abstract] [Full Text] [Related]

  • 5. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
    Galli M, Nicolucci A, Valentini M, Belfiglio M, Delaini F, Crippa C, Barbui AM, Giussani U, Rambaldi A, Barbui T.
    Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437
    [Abstract] [Full Text] [Related]

  • 6. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, Tangen JM, Westin J, Nordic Myeloma Study Group.
    Cancer; 2008 Jan 01; 112(1):129-35. PubMed ID: 17973267
    [Abstract] [Full Text] [Related]

  • 7. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, van Marwijk Kooy M, Meinema J, Nieuwenhuis HK, van Oers MH, Richel DJ, Segeren CN, Veth G, Verdonck LF, Wijermans PW.
    Bone Marrow Transplant; 1999 Feb 01; 23(4):317-22. PubMed ID: 10100574
    [Abstract] [Full Text] [Related]

  • 8. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B, German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL).
    Cancer; 2006 Jan 01; 106(1):136-45. PubMed ID: 16331635
    [Abstract] [Full Text] [Related]

  • 9. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
    Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P, Group Myelome-Autogreffe.
    J Clin Oncol; 2005 Dec 20; 23(36):9227-33. PubMed ID: 16275936
    [Abstract] [Full Text] [Related]

  • 10. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution.
    Magagnoli M, Castagna L, Balzarotti M, Sarina B, Timofeeva I, Bertuzzi A, Compasso S, Nozza A, Siracusano L, Santoro A.
    Am J Hematol; 2003 Aug 20; 73(4):267-72. PubMed ID: 12879431
    [Abstract] [Full Text] [Related]

  • 11. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J, Bladé J, Lahuerta JJ, Ribera JM, Martínez R, Alegre A, García-Laraña J, Fernández P, Sureda A, de Arriba F, Carrera D, Besalduch J, García Boyero R, Palomera Bernal L, Hernández MT, García PR, Pérez-Calvo J, Alcalá A, Casado LF, San Miguel J.
    Haematologica; 2006 May 20; 91(5):621-7. PubMed ID: 16627253
    [Abstract] [Full Text] [Related]

  • 12. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr 20; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 13. Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
    Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J, Tricot G, Alexanian R.
    Bone Marrow Transplant; 1998 Jun 20; 21(11):1101-7. PubMed ID: 9645572
    [Abstract] [Full Text] [Related]

  • 14. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma.
    Einsele H, Bamberg M, Budach W, Schmidberger H, Hess CF, Wörmann B, Meisner C, Straka C, Hebart H, Trümper L, Kröger N, Zander AR, Hegewisch-Becker S, Hossfeld DK, Schmidt H, Müller P, Schlimok G, Hertenstein B, Peest D, Metzner B, Frickhofen N, Kanz L, Bensinger WI.
    Bone Marrow Transplant; 2003 Sep 20; 32(6):593-9. PubMed ID: 12953132
    [Abstract] [Full Text] [Related]

  • 15. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
    Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.
    J Clin Oncol; 2006 Feb 20; 24(6):929-36. PubMed ID: 16432076
    [Abstract] [Full Text] [Related]

  • 16. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
    Bilgrami S, Bona RD, Edwards RL, Li Z, Naqvi B, Shaikh A, Furlong F, Fox J, Clive J, Tutschka PJ.
    Bone Marrow Transplant; 2001 Jul 20; 28(2):137-43. PubMed ID: 11509931
    [Abstract] [Full Text] [Related]

  • 17. [High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma remaining in initial remission: results of a feasibility study].
    Kitajima H, Nasu K, Tsudo M, Fujimoto M, Hayashi K, Ohno H, Konaka Y, Katsurada T, Arima N, Doi S, Moriguchi T, Fukuhara S.
    Rinsho Ketsueki; 2001 Mar 20; 42(3):191-8. PubMed ID: 11345781
    [Abstract] [Full Text] [Related]

  • 18. A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma.
    Corso A, Arcaini L, Caberlon S, Zappasodi P, Mangiacavalli S, Lorenzi A, Rusconi C, Troletti D, Maiocchi MA, Pascutto C, Morra E, Lazzarino M.
    Haematologica; 2002 Oct 20; 87(10):1041-5. PubMed ID: 12368158
    [Abstract] [Full Text] [Related]

  • 19. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity.
    Gojo I, Guo C, Sarkodee-Adoo C, Meisenberg B, Fassas A, Rapoport AP, Cottler-Fox M, Heyman M, Takebe N, Tricot G.
    Bone Marrow Transplant; 2004 Jul 20; 34(1):69-76. PubMed ID: 15133484
    [Abstract] [Full Text] [Related]

  • 20. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.
    Am J Hematol; 2006 Dec 20; 81(12):973-8. PubMed ID: 16888786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.